Naratriptan - Medication and Pregnancy KB

Naratriptan

Exposed non-exposed studies (cohort)

Study	Country Study period	Population source	Exposure definition	Non-exposure definition	Sample size	Rmk
Ephross (Naratriptan versus Sumatriptan), 2014	Worlwide 1996 - 2012	Women were eligible for enrollment by their health care provider if they were pregnant, exposed to sumatriptan, naratriptan, or the sumatriptan/naproxen sodium combination product at any time during pregnancy (beginning from the first day of the last menstrual period)	Pregnant women exposed to naratriptan at any time during pregnancy (beginning from the first day of the last menstrual period).	exposed to other treatment, sick Pregnant women exposed to sumatriptan at any time during pregnancy (beginning from the first day of the last menstrual period).	57 / 626	PV registry of GlaxoSmithKline. Exposure to sumatriptan and naratriptan provided and considered as separate subgroups.
Källén (control exposed to ergots), 2011	Sweden 1995 - 2008	All deliveries in Sweden (1 211 670 women) recorded in the Medical Birth Register with data from antenatal care.	Infants born to women who had used Naratriptan during pregnancy. (This is a subgroup of exposure among the whole exposed group considered in the study).	exposed to other treatment, sick Infants born to women who had used Ergots drugs for migraine during pregnancy. (This is a subgroup of exposure among the whole exposed group considered in the study).	22 / 527	Exposed groups of the whole study: drugs for migraine (ergots or triptans).
Källén (control unexposed, disease free), 2011	Sweden 1995 - 2008	All deliveries in Sweden (1 211 670 women) recorded in the Medical Birth Register with data from antenatal care.	Infants born to women who had used Naratriptan during pregnancy. (This is a subgroup of exposure among the whole exposed group considered in the study).	unexposed, disease free Infants born to women who did not use drugs for migraine.	22 / 1229901	Exposed groups of the whole study: drugs for migraine (ergots or triptans). 1229901= Total number of infants (n=1233228) - Number of infants whose mother used drugs for migraine in 1st trimester (n=3327)
Spielmann (Control mainly exposed other treatments, sick), 2017	Germany 1999 - 2014	Cohort of pregnant women enrolled by the German Embryotox system for risk assessment related to pregnancy.	Pregnant women with Naratriptan use for migraine disorder any time from conception to delivery. (This is a subgroup of exposure among the whole exposed group considered in the study).	exposed to other treatment, sick Pregnant women suffering from migraine disorder but not taking triptans between their last menstrual period and delivery.	42 / 475	The majority of exposed women took triptans in the first trimester (75.2%). Sumatriptan was the most frequently used triptan. Other triptans also studied.
Spielmann (Control unexposed, disease free), 2017	Germany 1999 - 2014	Cohort of pregnant women enrolled by the German Embryotox system for risk assessment related to pregnancy.	Pregnant women with Naratriptan use for migraine disorder any time from conception to delivery. (This is a subgroup of exposure among the whole exposed group considered in the study).	unexposed, disease free Pregnant women without migraine disorder who were neither exposed to triptans nor to one of the following established teratogens or fetotoxicant.	42 / 1733	The majority of exposed women took triptans in the first trimester (75.2%). Sumatriptan was the most frequently used triptan. Other triptans also studied.
Yusuf (Control exposed to Sumatriptan), 2018	The United States 1996 - 2012	Women with a diagnosis of migraine (International Classification of Diseases, Ninth Revision, diagnosis codes 346.xx) or prescription claims for migraine‐specific acute medications (triptans or ergotamine‐derivatives).	Pregnant women with migraine exposed to Naratriptan during pregnancy using an insurance administrative claims database.	exposed to other treatment, sick Pregnant women with migraine exposed to Sumatriptan during pregnancy using an insurance administrative claims database.	230 / 4519	This study was funded by Amgen and was conceived and conducted by Amgen employees.

Case-control studies (cohort)

Study	Country Study period	Case	Control	Sample size	Rmk

Warning! There are no case-control studies available for this drug.

master protocol